Effective-component compatibility of Bufei Yishen formula II inhibits mucus hypersecretion of chronic obstructive pulmonary disease rats by regulating EGFR/PI3K/mTOR signaling.
Animals
Bronchi
/ pathology
Cytokines
/ metabolism
Drugs, Chinese Herbal
/ pharmacology
ErbB Receptors
/ metabolism
Inflammation
/ metabolism
Lung
/ drug effects
Mucus
/ metabolism
Phosphatidylinositol 3-Kinases
/ metabolism
Pulmonary Disease, Chronic Obstructive
/ metabolism
Rats, Sprague-Dawley
Signal Transduction
/ drug effects
TOR Serine-Threonine Kinases
/ metabolism
Astragaloside IV (PubChem CID: 13943297)
Bufei yishen formula
Chronic obstructive pulmonary disease
Effective-component compatibility
Ethanol (PubChem CID: 702)
Formaldehyde (PubChem CID: 712)
Formalin (PubChem CID: 712)
Hesperidin (PubChem CID: 10621)
Icariin (PubChem CID: 5318997)
Mucus hypersecretion
Nobiletin (PubChem CID: 72344)
Paeoniflorin (PubChem CID: 442534)
Paeonol (PubChem CID: 11092)
Peiminine (PubChem CID: 167691)
Phosphate-buffered saline (PubChem CID: 24978514)
Schisandrin B (PubChem CID: 158103)
Xylene (PubChem CID: 7237)
Journal
Journal of ethnopharmacology
ISSN: 1872-7573
Titre abrégé: J Ethnopharmacol
Pays: Ireland
ID NLM: 7903310
Informations de publication
Date de publication:
15 Jul 2020
15 Jul 2020
Historique:
received:
31
10
2019
revised:
07
03
2020
accepted:
23
03
2020
pubmed:
29
4
2020
medline:
20
2
2021
entrez:
29
4
2020
Statut:
ppublish
Résumé
The effective-component compatibility of Bufei Yishen formula I (ECC-BYF I), a combination of 10 compounds, including total ginsenosides, astragaloside IV, icariin, and paeonol, etc., is derived from Bufei Yishen formula (BYF). The efficacy and safety of ECC-BYF I is equal to BYF. However, the composition of ECC-BYF I needs to be further optimized. Based on the beneficial effects of BYF and ECC-BYF I on chronic obstructive pulmonary disease (COPD), this study aimed to optimize the composition of ECC-BYF I and to explore the effects and mechanisms of optimized ECC-BYF I (ECC-BYF II) on mucus hypersecretion in COPD rats. ECC-BYF I was initially optimized to six groups: optimized ECC-BYF I (OECC-BYF I)-A~F. Based on a COPD rat model, the effects of OECC-BYF I-A~F on COPD rats were evaluated. R-value comprehensive evaluation was used to evaluate the optimal formula, which was named ECC-BYF II. The changes in goblet cells and expression of mucins and the mRNA and proteins involved in the epidermal growth factor receptor/phosphoinositide-3-kinase/mammalian target of rapamycin (EGFR/PI3K/mTOR) pathway were evaluated to explore the effects and mechanisms of ECC-BYF II on mucus hypersecretion. ECC-BYF I and its six optimized groups, OECC-BYF I-A~F, had beneficial effects on COPD rats in improving pulmonary function and lung tissue pathology, reducing inflammation and oxidative stress, and improving the protease/anti-protease imbalance and collagen deposition. R-value comprehensive evaluation found that OECC-BYF I-E (paeonol, icariin, nobiletin, total ginsenoside, astragaloside IV) was the optimal formula for improving the comprehensive effects (lung function: V ECC-BYF II, which consists of paeonol, icariin, nobiletin, total ginsenoside and astragaloside IV, has beneficial effects equivalent to BYF and ECC-BYF I on COPD rats. ECC-BYF II significantly inhibited mucus hypersecretion, which may be related to the regulation of the EGFR/PI3K/mTOR pathway.
Identifiants
pubmed: 32344236
pii: S0378-8741(19)34346-6
doi: 10.1016/j.jep.2020.112796
pii:
doi:
Substances chimiques
Bu-Fei-Yi-Shen
0
Cytokines
0
Drugs, Chinese Herbal
0
Egfr protein, rat
EC 2.7.10.1
ErbB Receptors
EC 2.7.10.1
TOR Serine-Threonine Kinases
EC 2.7.11.1
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
112796Informations de copyright
Copyright © 2020 Elsevier B.V. All rights reserved.